PictureRx: An Intervention to Reduce Latino Health Disparities
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37211
- Saint Thomas Family Health Center - South
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diabetes
- Latino, Spanish speaker
- Be at least 18 years old
- Must be taking at least 1 chronic medication
Exclusion Criteria:
- Too ill to participate in an interview
- Do not have a telephone
- Having visual acuity worse than 20/50 via Rosenbaum Visual Acuity exam (eyechart)
- Inability to communicate in either Spanish or English
- Overt psychiatric illnesses, overt delirium or dementia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
Usual care
|
|
|
Experimental: PictureRx cards
Illustrated format of medication instructions that includes pictures of pills and icons to show their purpose
|
An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Understanding of their Medication Regimen
Time Frame: Approximately 1 week after enrollment
|
The primary outcome will be patients' understanding of their medication regimen, as assessed by an interviewer-administered questionnaire.
|
Approximately 1 week after enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Self-reported Adherence
Time Frame: Approximately 1 week after enrollment
|
As a secondary outcome, patients will report their self-reported adherence using a validated instrument.
|
Approximately 1 week after enrollment
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: M Brian Riley, MA, PictureRx, LLC
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 1R43MD004048 (U.S. NIH Grant/Contract)
- 5R43MD004048-02 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
NCT05168657CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1
-
NCT07011147RecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin
-
NCT03811470RecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes Mellitus
-
NCT07463209Not yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)
-
NCT02631902CompletedType 2 Diabetes Mellitus | Diabetes-Related Complications
-
NCT07148713RecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes Education
-
NCT05284071CompletedDiabetes type1 | Diabetes type2
-
NCT01745900UnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent Diabetes
-
NCT06783309RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)
-
NCT03558867CompletedType 2 Diabetes Mellitus | Pre Diabetes
Clinical Trials on PictureRx card
-
NCT01622686CompletedMedication Adherence | Health Behavior
-
NCT02289469CompletedMedication Reconciliation
-
NCT06666868Not yet recruitingVaccination | Vaccination Reaction | Vaccination Pain | Vaccination Pharmacy
-
NCT07371026Not yet recruitingPediatric | Pediatric Acute Upper Respiratory Tract Infection | Pediatric Acute Respiratory Failure
-
NCT04917783CompletedSickle Cell Disease
-
NCT01158690CompletedIntimate Partner Violence
-
NCT02820129CompletedPolypharmacy | Medication Therapy Management | Comorbidity
-
NCT02093078CompletedObstetrical Emergency Situations
-
NCT01720641CompletedPartner Notification Following STI Diagnosis
-
NCT00457301CompletedChronic Obstructive Pulmonary Disease | Pulmonary Fibrosis | Cystic Fibrosis | Pulmonary Hypertension